SCHEMBL35211614

SCHEMBL35211614

Nc1nc2ccc(Cl)c(Br)c2s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.52
MAPT P10636 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 2/20 0.38
CYP2D6 P10635 1/20 0.38
RAB9A P51151 3/20 0.37
LMNA P02545 2/20 0.37
AXL P30530 1/20 0.37
GFER P55789 1/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PDE10A Q9Y233 1/20 0.37
CYP3A4 P08684 2/20 0.36
NPC1 O15118 2/20 0.34
SCN4A P35499 2/20 0.34
EPHX2 P34913 1/20 0.34
KDM4E B2RXH2 1/20 0.34
PKM P14618 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2069631 0.81 SMN1; SMN2 (0.55) SMN1; SMN2MAPTALDH1A1CYP1A2CYP2D6
SCHEMBL8379060 0.81 MAPT (0.45) SMN1; SMN2MAPTALDH1A1CYP1A2RAB9A
SCHEMBL26927627 0.78 SMN1; SMN2 (0.52) SMN1; SMN2MAPTALDH1A1CYP1A2CYP2D6
SCHEMBL12210717 0.78 SMN1; SMN2 (0.43) SMN1; SMN2MAPTALDH1A1CYP1A2RAB9A
SCHEMBL20855167 0.78 SMN1; SMN2 (0.49) SMN1; SMN2MAPTALDH1A1CYP1A2RAB9A
SCHEMBL17610010 0.78 SMN1; SMN2 (0.52) SMN1; SMN2MAPTALDH1A1CYP1A2CYP2D6
SCHEMBL659725 0.78 AXL (0.44) SMN1; SMN2MAPTALDH1A1CYP1A2RAB9A
Nitrogen SCHEMBL27684817 0.78 SMN1; SMN2 (0.52) SMN1; SMN2MAPTALDH1A1CYP1A2CYP2D6
SCHEMBL22993546 0.77 ALDH1A1 (0.55) SMN1; SMN2MAPTALDH1A1CYP1A2RAB9A
SCHEMBL35212496 0.74 SCN4A (0.45) SMN1; SMN2MAPTALDH1A1CYP1A2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124205-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS INC (US) 2026-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124205-A1 MODULATORS OF BETA CATENIN AND USES THEREOF CTNNB1, CTNNA1, CTNND1 SMN1; SMN2 2898/4885MAPT 4207/4885ALDH1A1 1195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.